LIPS-B: Lung Injury Prevention Study With Budesonide and Beta
This study is not yet open for participant recruitment.
Verified March 2013 by Mayo Clinic
Sponsor:
Mayo Clinic
Collaborators:
Stanford University
Beth Israel Deaconess Medical Center
Information provided by (Responsible Party):
Emir Festic, Mayo Clinic
ClinicalTrials.gov Identifier:
NCT01783821
First received: January 31, 2013
Last updated: March 14, 2013
Last verified: March 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
THE STUDY WILL ANSWER WHETHER INHALED BUDESONIDE AND FORMOTEROL ARE ABLE TO ALLEVIATE OR PREVENT PULMONARY INJURY WHEN ADMINISTERED EARLY IN HOSPITAL COURSE TO THE PATIENTS AT RISK FOR DEVELOPING ARDS
| Condition | Intervention | Phase |
|---|---|---|
|
Acute Respiratory Distress Syndrome (ARDS) |
Drug: Budesonide and formoterol Drug: Placebo |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Prevention |
| Official Title: | LIPS-B: Lung Injury Prevention Study With Budesonide and Beta Agonist (Formoterol) |
Resource links provided by NLM:
Further study details as provided by Mayo Clinic:
Primary Outcome Measures:
- Change in oxygen saturation to fraction of inspired oxygen concentration (S/F) ratio [ Time Frame: Change in S/F ratio from baseline to day 5 after the first treatment ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 60 |
| Study Start Date: | May 2013 |
| Estimated Study Completion Date: | December 2014 |
| Estimated Primary Completion Date: | September 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: budesonide and formoterol
Budesonide and formoterol
|
Drug: Budesonide and formoterol
Patients randomized to one of two intervention arms, will receive combined standard aerosolized doses of budesonide (0.5 mg) and formoterol (20 mcg) every 12 hours, for 5 days or until hospital discharge or death, with the first dose administered as soon as possible following randomization but not later than 4 hours.
|
|
Placebo Comparator: Placebo
Normal saline, the quantity and appearance same as the intervention arm.
|
Drug: Placebo |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Adult patients (age > 18);
- Admitted to the hospital through the emergency department (ED);
- High risk of developing ARDS (Lung Injury Prediction Score-LIPS greater than or equal to four;
- New chest radiograph performed on clinical grounds
Exclusion Criteria:
- Inhaled corticosteroid and/or beta agonist treatment on admission or within 7 days prior to admission (history of asthma or COPD necessitating therapy)
- Chronic pulmonary disease requiring daytime oxygen supplementation therapy
- Systemic steroid treatment on admission or within 7 days prior to admission equivalent to more than 5 mg of prednisone daily
- Inability to obtain consent within 12 hours of hospital presentation
- Acute lung injury prior to randomization
- Receiving mechanical ventilation before current hospital admission (patient who is ventilator dependent)
- Presentation believed to be purely due to heart failure without other known risk factors for ARDS
- Allergy or other contraindication to either budesonide and/or formoterol use
- Expected hospital stay and/or survival <48 hours or admission for comfort or hospice care
- Patient, surrogate or physician not committed to full support (exception: a patient will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest)
- Previous enrollment in this trial.
- Co-enrollment with LIPS-A trial is not allowed.
- An active enrollment in other concomitant trial will be judged on case by case basis by PIs of both trials.
- EKG and/or clinical presentation suggestive of acute coronary ischemia
- New onset cardiac arrhythmia
- Current atrial fibrillation with ventricular rate of >110/minute
- Persistent sinus tachycardia of >130/minute despite early goal directed therapy with fluids, pressors, antibiotics and supplemental oxygen Pregnant patients
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01783821
Locations
| United States, California | |
| Stanford University | Not yet recruiting |
| Stanford, California, United States | |
| Contact: Rosemary Vojnik rvojnik@stanford.edu | |
| Principal Investigator: Joseph E Levitt, MD | |
| United States, Florida | |
| Mayo Clinic in Florida | Recruiting |
| Jacksonville, Florida, United States, 32224 | |
| Contact: Pamela Long, BSN 904-953-7719 long.pamela@mayo.edu | |
| Contact: Kellie Ruday, BS (904) 9537766 ruday.kellie@mayo.edu | |
| Principal Investigator: Emir Festic, M.D. | |
| United States, Massachusetts | |
| Beth Israel Medical Center | Not yet recruiting |
| Boston, Massachusetts, United States | |
| Contact: Valerie Goodspeed vgoodspe@bidmc.harvard.edu | |
| Principal Investigator: Daniel Talmor, MD | |
| United States, Minnesota | |
| Mayo Clinic in Rochester | Not yet recruiting |
| Rochester, Minnesota, United States, 55905 | |
| Contact: Richard Hinds hinds.richard@mayo.edu | |
| Principal Investigator: Rodrigo Cartin-Ceba, MD | |
Sponsors and Collaborators
Mayo Clinic
Stanford University
Beth Israel Deaconess Medical Center
Investigators
| Principal Investigator: | Emir Festic, MD | Mayo Clinic |
More Information
No publications provided
| Responsible Party: | Emir Festic, M.D., Mayo Clinic |
| ClinicalTrials.gov Identifier: | NCT01783821 History of Changes |
| Other Study ID Numbers: | 12-008192 |
| Study First Received: | January 31, 2013 |
| Last Updated: | March 14, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Mayo Clinic:
|
Acute respiratory distress syndrome (ARDS) |
Additional relevant MeSH terms:
|
Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Respiratory Tract Diseases Respiratory System Agents Lung Injury Lung Diseases Respiration Disorders Infant, Premature, Diseases Infant, Newborn, Diseases Thoracic Injuries Wounds and Injuries Budesonide Formoterol Bronchodilator Agents |
Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Anti-Asthmatic Agents Therapeutic Uses Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Anti-Inflammatory Agents Adrenergic beta-2 Receptor Agonists Adrenergic beta-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents |
ClinicalTrials.gov processed this record on June 18, 2013